Evidence map›Paper›PMID 39510141›Full record

ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2025

Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer.

Jarey H Wang, Matthew P Deek, Adrianna A Mendes, Yang Song, Amol Shetty, Soha Bazyar, Kim Van der Eecken, Emmalyn Chen, Timothy N Showalter, Trevor J Royce and 19 more

Abstract readMulticenter StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Modern integrative prostate cancer diagnostics.Current opinion in urology · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Jarey H WangJohns Hopkins University, Baltimore, MD, USA.
Matthew P DeekRutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Adrianna A MendesJohns Hopkins University, Baltimore, MD, USA.
Yang SongJohns Hopkins University, Baltimore, MD, USA.
Amol ShettyUniversity of Maryland Medical Center, Baltimore, MD, USA.
Soha BazyarUniversity of Maryland Medical Center, Baltimore, MD, USA.
Kim Van der EeckenGhent University Hospital, Ghent, Belgium.
Emmalyn ChenArtera Inc., Los Altos, CA, USA.
Timothy N ShowalterArtera Inc., Los Altos, CA, USA; University of Virginia, Charlottesville, VA, USA.
Trevor J RoyceArtera Inc., Los Altos, CA, USA.
Tamara TodorovicArtera Inc., Los Altos, CA, USA.
Huei-Chung HuangArtera Inc., Los Altos, CA, USA.
Scott A HouckArtera Inc., Los Altos, CA, USA.
Rikiya YamashitaArtera Inc., Los Altos, CA, USA.
Ana P KiessJohns Hopkins University, Baltimore, MD, USA.
Daniel Y SongJohns Hopkins University, Baltimore, MD, USA.
Tamara LotanJohns Hopkins University, Baltimore, MD, USA.
Theodore DeWeeseJohns Hopkins University, Baltimore, MD, USA.
Luigi MarchionniWeill Cornell Medical College, New York, NY, USA.
Lei RenUniversity of Maryland Medical Center, Baltimore, MD, USA.
Amit SawantUniversity of Maryland Medical Center, Baltimore, MD, USA.
Nicole SimoneThomas Jefferson University, Philadelphia, PA, USA.
Alejandro BerlinPrincess Margaret Cancer Centre, Toronto, Canada.
Cem OnalBaskent University, Ankara, Turkey.
Andre EstevaArtera Inc., Los Altos, CA, USA.
Felix Y FengArtera Inc., Los Altos, CA, USA; University of California San Francisco, San Francisco, CA, USA.
Phuoc T TranUniversity of Maryland Medical Center, Baltimore, MD, USA. Electronic address: phuoc.tran@umm.edu.
Philip SuteraUniversity of Rochester Medical Center, Rochester, NY, USA. Electronic address: philip_sutera@urmc.rochester.edu.
Piet OstDepartment of Human Structure and Repair, Ghent University, Ghent, Belgium; Department of Radiation Oncology, Iridium Network, Antwerp, Belgium. Electronic address: piet.ost@ugent.be.

Funding

Resource Sharing CoreU54CA273956 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Phuoc T. Tran · 2022 to 2026
$8.9M
Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLCR01CA271540 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Phuoc T. Tran · 2023 to 2026
$2.3M
NCI NIH HHS R01 CA271540NCI NIH HHS U54 CA273956
6 · The paper itself

Abstract

backgroundThere is a need for clinically actionable prognostic and predictive tools to guide the management of oligometastatic castration-sensitive prostate cancer (omCSPC).

methodsThis is a multicenter retrospective study to assess the prognostic and predictive performance of a multimodal artificial intelligence biomarker (MMAI; the ArteraAI Prostate Test) in men with omCSPC (n = 222). The cohort also included 51 patients from the STOMP and ORIOLE phase 2 clinical trials which randomized patients to observation versus metastasis-directed therapy (MDT). MMAI scores were computed from digitized histopathology slides and clinical variables. Overall survival (OS) and time to castration-resistant prostate cancer (TTCRPC) were assessed for the entire cohort from time of diagnosis. Metastasis free survival (MFS) was assessed for the trial cohort from time of randomization.

resultsIn the overall cohort, patients with a high MMAI score had significantly worse OS (HR = 6.46, 95 % CI = 1.44-28.9; p = 0.01) and shorter TTCRPC (HR = 2.07, 95 % CI = 1.15-3.72; p = 0.015). In a multivariable Cox model, MMAI score remained the only variable significantly associated with OS (HR = 6.51, 95 % CI = 1.32-32.2; p = 0.02). In the subset of patients randomized in the STOMP and ORIOLE trials, high MMAI score corresponded to improved MFS with MDT (p = 0.039) compared to patients with a low score, with p

conclusionThe ArteraAI MMAI biomarker is prognostic for OS and TTCRPC among patients with omCSPC and may predict for response to MDT. Further work is needed to validate the MMAI biomarker in a broader mCSPC cohort.

Indexed as

Artificial IntelligenceAgedAged, 80 and overBiomarkers, TumorHumansMaleMiddle AgedNeoplasm MetastasisPrognosisProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantRetrospective StudiesBiomarkers, Tumor

Identifiers

PMID39510141
PMCPMC11663099

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.